Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer

Petra Petranović Ovčariček; Alfredo Campenni; Bart de Keizer; Desiree Deandreis; Michael C. Kreissl; Alexis Vrachimis; Murat Tuncel; Luca Giovanella

doi:10.3390/cancers15174290

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer

Petra Petranović Ovčariček^*
, Alfredo Campenni
, Bart de Keizer
, Desiree Deandreis
, Michael C. Kreissl
, Alexis Vrachimis
, Murat Tuncel
, Luca Giovanella

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

4 Downloads (Pure)

Abstract

Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [¹⁸F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC.

Original language	English
Article number	4290
Pages (from-to)	1-15
Journal	Cancers
Volume	15
Issue number	17
DOIs	https://doi.org/10.3390/cancers15174290
Publication status	Published - Sept 2023

Keywords

FAPI
FDG
molecular imaging
PRRT
PSMA
radioiodine-refractory DTC
radioligand therapy
somatostatin analogues
theranostics

Access to Document

10.3390/cancers15174290Licence: CC BY

cancers-15-04290Final published version, 1.84 MBLicence: CC BY

Cite this

@article{f362fe8bff214038b76fabda70016b6f,

title = "Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer",

abstract = "Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [18F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC.",

keywords = "FAPI, FDG, molecular imaging, PRRT, PSMA, radioiodine-refractory DTC, radioligand therapy, somatostatin analogues, theranostics",

author = "\{Petranovi{\'c} Ov{\v c}ari{\v c}ek\}, Petra and Alfredo Campenni and \{de Keizer\}, Bart and Desiree Deandreis and Kreissl, \{Michael C.\} and Alexis Vrachimis and Murat Tuncel and Luca Giovanella",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = sep,

doi = "10.3390/cancers15174290",

language = "English",

volume = "15",

pages = "1--15",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "17",

}

TY - JOUR

T1 - Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer

AU - Petranović Ovčariček, Petra

AU - Campenni, Alfredo

AU - de Keizer, Bart

AU - Deandreis, Desiree

AU - Kreissl, Michael C.

AU - Vrachimis, Alexis

AU - Tuncel, Murat

AU - Giovanella, Luca

PY - 2023/9

Y1 - 2023/9

N2 - Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [18F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC.

AB - Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [18F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC.

KW - FAPI

KW - FDG

KW - molecular imaging

KW - PRRT

KW - PSMA

KW - radioiodine-refractory DTC

KW - radioligand therapy

KW - somatostatin analogues

KW - theranostics

UR - https://www.scopus.com/pages/publications/85170379677

U2 - 10.3390/cancers15174290

DO - 10.3390/cancers15174290

M3 - Review article

AN - SCOPUS:85170379677

SN - 2072-6694

VL - 15

SP - 1

EP - 15

JO - Cancers

JF - Cancers

IS - 17

M1 - 4290

ER -

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this